All Medicines
Dr. Aditya Singh

Medically Reviewed By

Dr. Aditya Singh, MBBS, MD (Pharmacology)

Reg No: MCI-654321 • Verified Medical Reviewer

Interleukin inhibitors

Ilaris

(canakinumab)

Uses, side effects, dosage information & price range

Novartis Europharm Limited

About this medicine

Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: Cryopyrin-associated periodic syndromes Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including: Muckle-Wells syndrome (MWS), Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA), Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash. Tumour necrosis factor receptor associated periodic syndrome (TRAPS) Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS). Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD). Familial Mediterranean fever (FMF) Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate. Ilaris is also indicated for the treatment of: Still’s disease Ilaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate. Gouty arthritis Ilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

Key Information

Salt / Composition

canakinumab

Category

Interleukin inhibitors

Manufacturer

Novartis Europharm Limited

Need a doctor's consultation?

Don't self-medicate. Consult a doctor before taking any medicine.

Medical Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.

Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.